Gladstone's Deepak Srivastava Honored as Most Admired CEO by San Francisco Business Times [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
SAN FRANCISCO May 10, 2024 /PRNewswire/ -- The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava , MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits. In an article now appearing in the weekly publication, Srivastava is noted for his inspiring leadership style and ability to successfully navigate both the nonprofit research landscape and the startup biotech world. Srivastava has led Gladstone since 2018, the third president in the organization's history. But he's played an instrumental role at Gladstone for nearly 20 years, having joined as director of the Gladstone Institute of Cardiovascular Disease in 2005. In addition to serving as president, Srivastava is a senior investigator at Gladstone, running a 20-person lab focused on gene networks that guide the development of the heart; his lab's discoveries have shed new light on genetic drivers of heart disease and uncovered novel strategies for repairing heart damage.
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting [Yahoo! Finance]Yahoo! Finance
TNYA
Earnings
- 5/14/24 - Beat
TNYA
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 4/17/24 - Form ARS
- TNYA's page on the SEC website